Clonazolam
Clonazolam is a highly potent depressant of the triazolobenzodiazepine class, structurally related to both clonazepam and alprazolam. First synthesized in 1971, it was never marketed pharmaceutically and has been available as a research chemical since the mid-2000s. It is considered to pose higher risks than many other designer benzodiazepines due to its exceptional potency, with strong sedation and amnesia reported at very low doses. Blackouts and dependence are frequently reported concerns.
Contents
Dosage & Duration
Dosage
Extremely potent; doses as small as 0.5 mg can produce strong sedation and amnesia, and doses above 0.5 mg can cause benzodiazepine overdose in some individuals. Onset may be delayed, with some users feeling little or nothing until 1-2 hours after administration; redosing is inadvisable at any point. Vendors often sell 500 ug products despite this exceeding a common dose.
Duration
Subjective Effects
Effects vary widely by individual, dose, and context.
Physical
The physical effects of clonazolam can be broken down into several components which progressively intensify proportional to dosage.
Cognitive
The cognitive effects of clonazolam can be broken down into several components which progressively intensify proportional to dosage. The general head space of clonazolam is described by many as one of intense sedation and decreased inhibition. It contains a large number of typical depressant cognitive effects. Paradoxical reactions to benzodiazepines such as increased seizures (in epileptics), aggression, increased anxiety, violent behavior, loss of impulse control, irritability and suicidal behavior sometimes occur (although they are rare in the general population, with an incidence rate below 1%). These paradoxical effects occur with greater frequency in recreational abusers, individuals with mental disorders, children, and patients on high-dosage regimes.
Reagent Testing
Loading reagent data
Pharmacology
Pharmacodynamics
Clonazolam acts as a positive allosteric modulator of GABA-A receptors at the benzodiazepine binding site, enhancing the activity of the inhibitory neurotransmitter GABA. It is notably potent, proving the most active compound in a series of triazolobenzodiazepines and sometimes effective at doses below 10 μg/kg in mice. The anticonvulsant properties of benzodiazepines may also involve binding to voltage-dependent sodium channels.
Pharmacokinetics
Clonazolam undergoes extensive metabolism in humans. The primary metabolic routes include reduction of the nitro group to form 7-aminoclonazolam (the most abundant urinary metabolite), which is subsequently acetylated to 7-acetaminoclonazolam. Monohydroxylation also occurs, most likely at the α- and 4-positions, yielding hydroxyclonazolam. These metabolites are further conjugated with glucuronic acid.
Tolerance
Benzodiazepines
Harm Potential
Addiction & Dependence
Psychological
Extremely HighClonazolam is considered extremely psychologically addictive with high abuse potential. Compulsive redosing is commonly reported, and the substance is noted for producing euphoria more frequently than many other benzodiazepines, which may increase its reinforcing properties. Rebound anxiety following use can facilitate cycles of dependence.
Physical
Extremely HighPhysical dependence can develop within days of regular use, and in some cases even after a single large dose. Withdrawal is potentially life-threatening and may include anxiety, insomnia, cognitive impairment, elevated blood pressure, increased heart rate, tremor, restlessness, and in severe cases psychosis and seizures. Abrupt discontinuation is strongly discouraged; gradual tapering under medical supervision is recommended.
Psychosis Risk
Psychosis is rare during intoxication but may occur during severe benzodiazepine withdrawal. Paradoxical reactions including aggression, violent behavior, and increased anxiety occur with an incidence below 1% in the general population but are more frequent in recreational abusers, individuals with mental disorders, and those on high-dose regimens.
Seizure Risk
Clonazolam possesses anticonvulsant properties during active use. However, abrupt discontinuation after regular use poses a significant seizure risk that can be life-threatening. Gradual tapering is essential for anyone who has developed physical dependence.
History & Culture
Clonazolam was first synthesized in 1971 by The Upjohn Company, the pharmaceutical corporation that would later bring alprazolam (Xanax) to market. In the original research, the compound was described as the most active substance in the series of triazolobenzodiazepines tested. Despite this notable…
Legality
By Country
Automated synthesisInformation aggregated and synthesized using an autonomous workflow built by Josie Kins.
Suggest an edit
Spotted a mistake, an outdated claim, or something missing from the Clonazolam article? Send the editors a private note. Feedback lands in a moderation queue and is never shown on the site.